Member Info for alphabravo321

https://www.nasdaq.com/market-activity/stocks/amyt/real-time

Nasdaq site has "AMYT" "Trading Held"

Thanks Bermuda, I had read the doc but missed that all important date, thanks very much

Have we a date published?

I am not implying one way or the other, decide for yourself, I am however happy that Amryt is Revenue generating and EBITDA positive with a relatively small m cap which is rare on NASDAQ, I have been holing this since Fastnet so far so good

Have a look through this list of all pharma on Nasdaq, there is a significant amount who are either loss making or have no revenue that have market caps in there billions....

https://topforeignstocks.com/stock-lists/the-complete-list-of-biotech-stocks-trading-on-nasdaq/

Looking at a few pharmas on Nasdaq, average tend to trade on 6-8 times earnings, we could be in for a nice q3/q4

Reported in Irish Times yesterday that Amryt say they expect Nasdaq listing to be complete within July

Yes but thats the first time AMYT has appeared on the Nasdaq website I believe

The application was RNS’d back in Feb

Wiley in the right with Amryt
Perhaps you should have paid attention in biology class. Joe Wiley, chief executive, and Rory Nealon, chief financial officer, were last week granted options over 10.2m shares in Amryt Pharma, an Irish drug developer. The bumper share awards have an exercise price of £1.215p each.

Amryt is an orphan drug specialist, finding treatments for rare diseases. The company recently acquired Aegerion, a Canadian peer and has a drug in development to treat the skin disease epidermolysis bullosa. There are no sure things in pharma, yet Wiley has a top reputation and a nose for a deal. The rewards here could be truly massive.

Wiley by name, wily by nature.

It is very clear in the admission doc that the shares are being bought and placed at 1.48, whether they stay there remains to be seen.

https://www.businesspost.ie/business/dublin-drug-companys-value-set-top-e280-million-wake-us-acquisition-451267

https://epidermolysisbullosanews.com/2019/08/16/amryt-oleogel-s10-phase-3-trial-design-epidermolysis-bullosa/

https://www.wsj.com/articles/aegerion-creditors-approve-drugmakers-chapter-11-plan-11566575038

What a load of biased ******. Not a single statement backed up by fact. Trump numpties

https://www.proactiveinvestors.co.uk/companies/news/211979/amryt-to-add-another-48-patients-to-phase-iii-trial-of-skin-disorder-cream-211979.html Last few paragraphs are interesting

It is interesting that although todays news although good is not the best we could have hopes for, that being said Anryt are much close to an approved EB treatment than Scioderm were when they were bought out by Amicus...will someone be willing to roll the dice and make an offer?

See above...zzz

So the article posted last week refers to the trial in 2015? The article made it seem more current